Abundant Produce signs new China-Australia export deal
Abundant Natural Health, which is 100% owned by Abundant Produce Limited (ASX:ABT), this morning informed the market it has entered into an International Supply Agreement with Jatenergy Limited (JAT).
The agreement, covering a period of 24 months from commencement with two 24-month options to renew, will include the Active Lyco TM Face Range and Magnesium Body and Salt Skin Range totalling six SKUs, which will be expanded in line with consumer demand.
JAT is an end-to-end export service provider offering a fast, cost effective, one-stop solution for Australian companies seeking to launch and build their brands in China. Recently, JAT’s shareholders approved the takeover of Golden Koala — a producer of Australian-made infant formula and milk products sold into China — further strengthening its position as a China-Australia border specialist.
ANH CEO Shanan Birkin said: “On the back of our recent HealthOne agreement, this is an exciting expansion of the distribution channel into the Chinese consumer marketplace.
“JAT will promote ANH’s scientifically developed, natural health range of face treatments and body creams and sprays to its vast consumer network in China. We intend to start fulfilment of the JAT supply chain immediately.”
JAT Executive Director, Wilton Yao also commented: “As ANH’s exclusive Chinese marketplace partner, JAT intends to create and facilitate strong relationships on behalf of ANH in this growing consumer market. Product quality and provenance are critical factors in supplying the Chinese market and ANH’s natural range meets these requirements 100%.
“Key to promoting ANH’s range in China is its focus on the scientific development of its products in collaboration with The University of Sydney and The University of NSW.”
ANH recently announced its partnership with HealthOne, which will represent ANH’s products in Australian pharmacies and specialist health focused outlets.
“ANH has partnered distribution and marketing partners, HealthOne and JAT, to capitalise on their deep operating understanding and knowledge of their respective marketplaces, which will ultimately drive sales growth,” Birkin said.
“We’re confident that HealthOne and JAT can successfully promote and sell our unique science and research-backed natural actives in the Australian and Chinese markets.”
ABT is a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.